Midatech Divests US Unit To Focus On Its Rival Drug To Novartis' Sandostatin LAR

UK-based Midatech will use money from its US divestment to ramp up R&D efforts and progress its key oncology product MTD201, which has a favorable clinical profile versus Novartis' blockbuster Sandostatin LAR, the biotech's CEO tells Scrip.

R&D
UK Biotech Selling US Affiliate To Raise Money For Pipeline Advancement • Source: Shutterstock

By divesting its subsidiary in the US, Midatech Pharma PLC aims to simplify its R&D strategy and raise needed money to repay debt and progress its proprietary platforms to improve the delivery and quality of existing drugs. In particular it will focus on its lead product, which seeks to better Novartis AG's blockbuster Sandostatin LAR (octreotide acetate), according to the British biotech's recently installed CEO.

Based on recent clinical data Midatech – which was spun out of Cardiff University five years ago - has entered...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.